Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen Anthony Stamp
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- 1.19
- Country
- GB
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -15.89
Financials
Revenue
$0.00-100.0%Net Income
$-1.88MEBITDA
$-4.67MFree Cash Flow
$-4.62MEPS (diluted)
$0.00Shares Outstanding (diluted)
14.9K+186512.5%Operating Expenses
$4.67MCash & Debt
$3.21MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-6.24M | $-400.00 |
| 2024 | $0.00 | $-5.73M | $-3705.65 |
| 2023 | $381.0K | $-7.08M | $-69640.00 |
| 2022 | $699.0K | $-7.66M | $-4770680.00 |
| 2021 | $578.0K | $-5.46M | $-4661590.00 |
| 2020 | $343.0K | $-22.19M | $-33209775.00 |
| 2019 | $674.0K | $-10.09M | $-35095575.00 |
| 2018 | $1.94M | $-10.37M | $-292803790.00 |
| 2017 | $989.0K | $-11.71M | $-397196150.00 |
| 2016 | $1.32M | $-6.16M | $-740868715.00 |
| 2015 | $1.38M | $-10.10M | $-536944425.00 |
| 2014 | $157.0K | $-8.82M | $-1577747295.00 |
| 2013 | $147.0K | $-4.08M | $-229264380.00 |
| 2012 | $0.00 | $-3.99M | $-216922555.00 |
Valuation
BDRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
83-16.67%Social Signal Score
Mentions (3)
- Newsaccessnewswire.com·13d ago·Negative
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which the only current remedy is surgical removal of the colon and/or rectum. Key takeaways: eRapa is an oral drug candidate designed to reduce or eliminate the need for surgical treatments; a Phase 3 registrational trial, run…
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
…ptember 11, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, today announces its unaudited interim results for the six months ended June 30, 2026 which will also be made available on the Company's website at https://biodexapharma.com/ . OPERATION…
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
…Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial of eRapa in Familial Adenom…
View source ↗
Earnings
Fri, Apr 23(in 7 months)
Typical surprise -2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Mar 27$-0.00 vs $-0.01beat
- Fri, Sep 12$-0.00 vs $-0.02beat
- Fri, Apr 11$-0.03 vs $-0.03miss
- Thu, Sep 26$-1.67 vs $-1.12miss
- Fri, Apr 19$-17.72 vs $-17.71miss
Estimates and results for BDRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BDRX officers and directors.
No open-market trades in the recent filings. All 12 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
12 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BDRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.